XML 61 R48.htm IDEA: XBRL DOCUMENT v3.22.1
SHARE-BASED PAYMENTS - Schedule of Share-based Compensation, Restricted Stock, Restricted Stock Units Activity and SAR's (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Payment Arrangement, Expense $ 862 $ 697  
Equity Option      
Weighted Average Grant Date Fair Value      
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) $ 1.34 $ 0.94 $ 0.94
Nonvested, weighted average grant date fair value, end of period (in dollars per share) $ 2.53   $ 1.34
Employee Stock Option      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Payment Arrangement, Expense $ 32 $ 200  
Weighted Average Grant Date Fair Value      
Unrecognized Compensation Costs Related To Unvested Stock Options 120    
Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Payment Arrangement, Expense $ 484 $ 362  
Number of Shares      
Granted, nonvested, number of shares (in shares) 330,000 440,000  
Weighted Average Grant Date Fair Value      
Unrecognized Compensation Costs Related To R S U Awards $ 2,310    
Restricted Stock Units (RSUs) | Equity Option      
Number of Shares      
Number of nonvested shares, beginning of period (in shares) 900,064 1,094,056 1,094,056
Granted, nonvested, number of shares (in shares) 329,377   441,241
Vested, number of shares (in shares) (518,856)   (635,233)
Number of nonvested shares, end of period (in shares) 710,585   900,064
Weighted Average Grant Date Fair Value      
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) $ 2.94 $ 1.98 $ 1.98
Granted, nonvested, weighted average grant date fair value (in dollars per share) 6.43   3.89
Vested, weighted average grant date fair value (in dollars per share) 2.93   1.94
Nonvested, weighted average grant date fair value, end of period (in dollars per share) $ 4.56   $ 2.94
Stock Appreciation Rights (SARs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Payment Arrangement, Expense $ 346 $ 135  
Number of Shares      
Number of nonvested shares, beginning of period (in shares) 1,672,422 1,720,623 1,720,623
Granted, nonvested, number of shares (in shares) 730,686    
Number of nonvested shares, end of period (in shares) 2,403,108   1,672,422
Weighted Average Grant Date Fair Value      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Exercise Price     $ 2.92
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) $ 2.92 $ 2.92 2.92
Granted, nonvested, weighted average grant date fair value (in dollars per share) 6.47    
Nonvested, weighted average grant date fair value, end of period (in dollars per share) $ 4.00   $ 2.92
Unrecognized Compensation Costs Related To R S U Awards $ 2,280    
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Number 1,098,873    
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised     48,201
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Exercise Price $ 2.92    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 2 years 8 months 23 days    
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Remaining Contractual Term 1 year 9 months 21 days    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding $ 12,377    
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Aggregate Intrinsic Value $ 6,846    
Stock Appreciation Rights (SARs) | Equity Option      
Number of Shares      
Number of nonvested shares, beginning of period (in shares) 573,549 1,720,623 1,720,623
Granted, nonvested, number of shares (in shares) 730,686    
Vested, number of shares (in shares)     (1,147,074)
Number of nonvested shares, end of period (in shares) 1,304,235   573,549
Weighted Average Grant Date Fair Value      
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) $ 1.19 $ 1.25 $ 1.25
Granted, nonvested, weighted average grant date fair value (in dollars per share) 3.60    
Vested, weighted average grant date fair value (in dollars per share)     1.27
Nonvested, weighted average grant date fair value, end of period (in dollars per share) $ 2.54   $ 1.19